Zobrazeno 1 - 10
of 134
pro vyhledávání: '"K P, Laktionov"'
Publikováno v:
Сибирский онкологический журнал, Vol 23, Iss 2, Pp 133-138 (2024)
Background. The use of the modern targeted drugs in patients with non-small-cell lung cancer (NSCLC) with certain somatic alterations (genetic alterations in EGFR, ALK, ROS1, BRAF, RET genes, etc.) provides a significant increase in overall and disea
Externí odkaz:
https://doaj.org/article/44c6ff27b6dd4ab285c7f9f699f1123c
Autor:
K. K. Laktionov, K. A. Sarantseva, L. A. Nelyubina, S. V. Gamayunov, E. A. Kolesnikova, M. G. Gordiev
Publikováno v:
Сибирский онкологический журнал, Vol 23, Iss 2, Pp 72-81 (2024)
Lung cancer remains one of the most dangerous and most common cancers, requiring constant improvement of diagnostic and treatment methods. The genetic heterogeneity of lung cancer forces us to search for new therapeutic targets in an attempt to achie
Externí odkaz:
https://doaj.org/article/73b447e88d214b60aa826941c8d2573c
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 2, Pp 56-64 (2023)
Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and metho
Externí odkaz:
https://doaj.org/article/711ddfebc8424d3c82687bb8d30323b2
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 172-177 (2022)
Non-small cell lung cancer is a very heterogeneous group of diseases. When choosing an effective patient management strategy, an oncologist focuses on the stage of the disease, the morphological form of the tumor, as well as its molecular genetic mar
Externí odkaz:
https://doaj.org/article/3afa4470b51643a49ee504769c39177e
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 157-162 (2022)
HCC is considered refractory when it comes to progression during treatment with TKIs (sorafenib, lenvatinib). The combined immunotherapy of nivolumab with ipilimumab was studied in the one cohort of CheckMate-040 study, excluding immunotherapy-naive
Externí odkaz:
https://doaj.org/article/88111f1fbbb34a1290aaebf398e8292a
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 14-20 (2022)
Lung cancer is one of the most common malignant tumors with the highest mortality, with about 85% of cases of the disease being non-small cell lung cancer. To date, adjuvant chemotherapy based on platinum preparations remains the standard of treatmen
Externí odkaz:
https://doaj.org/article/d9480ee32534481e8bfbc13818ee51ec
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 1, Pp 115-121 (2022)
The purpose of the study: to conduct a systematic literature review on the effectiveness and feasibility of using information on the presence of KRAS gene mutations (in different codons), TP 53 (KP), ST K11/LKB1 (KL), and KEAP mutations and the assoc
Externí odkaz:
https://doaj.org/article/d70e95fee7884b2bb385696709255c81
Autor:
E. Yu. Antonova, E. A. Moroz, D. V. Podluzhny, N. E. Kudashkin, I. A. Dzhanyan, A. Yu. Volkov, K. K. Laktionov, V. V. Breder
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 94-100 (2021)
Introduction. Fibrolamellar hepatocellular carcinoma (FLC), which develops most often in the younger population. In FLC, variable histoarchitectonics are noted, possibly the presence of a sclerosing component, foci of necrosis and dystrophy of tumor
Externí odkaz:
https://doaj.org/article/0fb253b580fd402d89fd7f26341a7465
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 62-67 (2021)
Introduction. Lorlatinib is a third generation ALK tyrosine kinase inhibitor. Back in 2018, the drug underwent accelerated FDA approval and was recommended for the treatment of patients with ALK-positive non-small cell lung cancer after progression o
Externí odkaz:
https://doaj.org/article/1c654f8c443e4a73bbe68d91b0c46fe5
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 150-154 (2021)
The optimal hepatocellular cancer (HCC) therapy remains a challenge. Due to checkpoint inhibitors patients with intolerance to the targeted therapy and or those with the impaired liver function can get an appropriate drug therapy. This clinical obser
Externí odkaz:
https://doaj.org/article/7d3b533bad6847ca98344d2b18409f5a